BCYCBicycle Therapeutics Plc - ADR
$4.18
$0.02
(0.48%)
EarningsAug 7
Mkt Cap$209.12M
Vol64,728.00
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced the presentation of initial data from the randomized Phase 2 trial (Duravelo-2) evaluating...
Business Wire
Bicycle Therapeutics (NASDAQ:BCYC) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen cut shares of Bicycle Therapeutics from a 'hold' rating to a 'sell' rating in a research report on Saturday...
MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Announces Earnings Results, Misses Estimates By $0.25 EPS
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts...
MarketBeat
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell re...
MarketBeat
Bicycle Therapeutics (BCYC) to Release Quarterly Earnings on Thursday
Bicycle Therapeutics (NASDAQ:BCYC) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at...
MarketBeat
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual...
Business Wire
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
<
1
2
...
>
Advertisement|Remove ads.
GOOGL8
12
SMCI15
18
RKLB4
7Advertisement|Remove ads.